Campus Centro Oeste Dona Lindu-Universidade Federal de São João del-Rei, Chanadour 400, Brazil.
Int J Mol Sci. 2019 Jul 14;20(14):3458. doi: 10.3390/ijms20143458.
Hypertension is characterized by structural and functional changes in blood vessels that travel with increased arterial stiffness, vascular inflammation, and endothelial dysfunction. Some antihypertensive drugs have been shown to improve endothelial function and reduce levels of inflammatory markers regardless of the effect of blood pressure lowering. Third-generation β-blockers, such as nebivolol and carvedilol, because they have additional properties, have been shown to improve endothelial function in patients with hypertension. Calcium channel antagonists, because they have antioxidant effects, may improve endothelial function and vascular inflammation.The Angiotensin Receptor Blocker (ARBs) are able to improve endothelial dysfunction and vascular inflammation in patients with hypertension and other cardiovascular diseases. Angiotensin converting enzyme (ACE) inhibitors have shown beneficial effects on endothelial function in patients with hypertension and other cardiovascular diseases, however there are few studies evaluating the effect of treatment with this class on the reduction of C-reactive protein (CRP) levels. Further studies are needed to assess whether treatment of endothelial dysfunction and vascular inflammation may improve the prognosis of patients with essential hypertension.
高血压的特征是血管的结构和功能发生变化,表现为动脉僵硬度增加、血管炎症和内皮功能障碍。一些降压药物已被证明可以改善内皮功能并降低炎症标志物水平,而不论其降压效果如何。第三代β受体阻滞剂,如奈必洛尔和卡维地洛,由于具有额外的特性,已被证明可以改善高血压患者的内皮功能。钙通道拮抗剂因其具有抗氧化作用,可能改善内皮功能和血管炎症。血管紧张素受体阻滞剂(ARBs)能够改善高血压和其他心血管疾病患者的内皮功能障碍和血管炎症。血管紧张素转换酶(ACE)抑制剂已显示出对高血压和其他心血管疾病患者内皮功能的有益影响,但是很少有研究评估此类药物治疗对 C 反应蛋白(CRP)水平降低的影响。需要进一步的研究来评估治疗内皮功能障碍和血管炎症是否可以改善原发性高血压患者的预后。